Phase 2 Randomized Study of PG-102 vs Placebo and Semaglutide in Type 2 Diabetes Mellitus

NCT07187856 on ClinicalTrials.gov · last registry update 2025-09-23

Registered but never opened — and the completion date on file, September 2026, has already passed. Its estimated completion date, September 2026, has passed with no update to the record. Primary outcome, as filed: Absolute change in HbA1c From Baseline at Week 24. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. semaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: NOT_YET_RECRUITING
Phase: P2
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: ProGen. Co., Ltd.
Sponsor type: Other
Enrollment: 80
Started: 2026-01
Primary completion: 2026-09 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Absolute change in HbA1c From Baseline at Week 24

Conditions studied

Type 2 Diabetes Mellitus (T2DM)

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.